A 3.5-year study of immune function in persons with hemophilia infusing recombinant factor VIII.
Brettler
D
D
New England Hemophilia Center, Medical Center Central Massachusetts, Memorial Hospital, Worcester 01605.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000917:Antibody Formation; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D005169:Factor VIII / Q000276:immunology / Q000627:therapeutic use*; D005500:Follow-Up Studies; D018023:HIV Seronegativity; D006679:HIV Seropositivity / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D015497:HIV-1; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D013997:Time Factors; D015215:Zidovudine / Q000627:therapeutic use
D011994:Recombinant Proteins; D015215:Zidovudine; D005169:Factor VIII